Mechanism of Action
CJC-1295 acts as a long-acting GHRH receptor agonist, stimulating GH secretion through the hypothalamic-pituitary axis.
DAC Technology and Albumin Binding
The Drug Affinity Complex on CJC-1295 reacts with circulating albumin via a Michael addition to form a stable covalent bond after subcutaneous injection. This creates an endogenous reservoir, albumin serves as a circulating depot, slowly releasing active CJC-1295 over days. Albumin's ~19-day half-life limits full duration to approximately 6-8 days for the peptide payload.[1]GHRH Receptor Activation
CJC-1295 binds GHRH receptors on pituitary somatotrophs, activating adenylyl cyclase via Gs protein coupling. This elevates intracellular cAMP, driving GH gene transcription and secretion. Unlike ghrelin receptor agonists (GHRPs), GHRH receptor activation specifically amplifies GH pulse amplitude without initiating new pulses.[1]Synergy with GHRPs
GHRH and GHRP act on different, complementary receptor systems. GHRH (via CJC-1295) primes somatotrophs and amplifies pulse amplitude; GHRPs (Ipamorelin, GHRP-2) initiate the pulsatile stimulus. The combination consistently produces GH pulses far exceeding either alone, a well-characterized pharmacological synergy.[2]Research Overview
GH and IGF-1 Elevation
Phase I/II ClinicalPhase I/II clinical trials in healthy adults demonstrated that a single CJC-1295 injection produces sustained GH elevation lasting 6+ days. Mean GH levels increased 2-10x above baseline for 6 days, with IGF-1 increases of 1.5-3x lasting 9-11 days after a single dose. Dose-proportional effects confirmed up to 30 mcg/kg.[1]
Body Composition and Recovery
Moderate EvidenceSustained IGF-1 elevation from CJC-1295 supports anabolic signaling, protein synthesis, and lipolysis. Preclinical models show improved body composition with chronic use. Human data is primarily from observational use in GH-deficient populations.[2]
Anti-aging Applications
EmergingGH and IGF-1 decline markedly with age, CJC-1295 protocols aim to restore younger GH/IGF-1 profiles. The once-weekly convenience distinguishes it from daily GHRH peptides. Data in healthy aging adults is limited but clinically evaluated.[1]
Calculate your CJC-1295 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Clinical Trial Data
| Phase | Trial | N | Duration | Key Outcome |
|---|---|---|---|---|
| Phase 1 | Ionescu & Frohman PK study PMID:16822818 | 12 | Single dose | Half-life 5.8-8.1 days confirmed; GH AUC elevated for 7 days; IGF-1 elevated 14+ days post-injection |
| Phase 2 | Teichman et al. GH deficiency PMID:17636088 | 28 | 6 weeks | Once-weekly CJC-1295 restores GH pulsatility in GH-deficient adults; IGF-1 normalization in majority of subjects |
| Phase 1 | Safety PK study (multiple doses) PMID:15741266 | 21 | Multiple doses | Well-tolerated up to 60 mcg/kg; flushing most common AE; no cortisol or prolactin elevation |
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Stacked with Ipamorelin | 1 mg CJC-1295 + 200-300 µg Ipamorelin | 2× weekly (CJC) + daily (Ipa) | Subcutaneous |
| GH elevation baseline | 1 mg | Once weekly | Subcutaneous |
| Anti-aging protocol | 2 mg | Once weekly | Subcutaneous |
| Conservative start | 1 mg | Once weekly | Subcutaneous |
CJC-1295 (with DAC) can be injected at any time of day given its multi-day half-life, timing precision is less critical than for short-acting GHRPs. Most protocols pair once-weekly CJC-1295 with daily Ipamorelin for daily GH pulses on an elevated GHRH background. Note: CJC-1295 WITHOUT DAC (Mod GRF 1-29) has a ~30-min half-life and requires different dosing (100-300 mcg per injection, 2-3x daily, timed like Ipamorelin).
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
CJC-1295 has been evaluated in human clinical trials and shows an acceptable safety profile at doses up to 30 mcg/kg.
WADA Status: Prohibited by WADA as a peptide hormone and growth factor. Athletes subject to testing must not use this compound.
Water retention: The most common reported effect, GH-driven sodium retention causes transient fluid retention. Usually mild and self-resolving.
Tunnel syndrome risk: Sustained supraphysiological GH/IGF-1 elevation has been associated with carpal tunnel syndrome in high-dose GH therapy. Monitor for tingling/numbness in hands with long protocols.
IGF-1 monitoring: Given the 9-11 day IGF-1 elevation per injection, monitoring IGF-1 levels quarterly is advisable for chronic users.
No FDA approval: Not approved for human therapeutic use.
References
- [1]Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." J Clin Endocrinol Metab. 2006;91(3):799-805. PMID:16352683
- [2]Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID:17062766